| 2.065 0.165 (8.68%) | 04-22 15:21 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.86 | 1-year : | 6.7 |
| Resists | First : | 4.16 | Second : | 5.73 |
| Pivot price | 2.38 |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 1.87  |
MA(20) : | 2.93 |
| MA(100) : | 4.85 |
MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 8.1 |
| RSI | RSI(14): 31.9 |
|||
| 52-week | High : | 12.3 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CAMP ] has closed above bottom band by 36.8%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.14 - 2.16 | 2.16 - 2.16 |
| Low: | 1.83 - 1.84 | 1.84 - 1.85 |
| Close: | 1.88 - 1.9 | 1.9 - 1.92 |
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Thu, 10 Apr 2025
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
Mon, 31 Mar 2025
CAMP4 Therapeutics Advances RNA-Based Therapeutics - TipRanks
Thu, 27 Mar 2025
CAMP4's $64M War Chest Powers Clinical Progress in Rare Disease Treatments - Stock Titan
Tue, 18 Mar 2025
Camp4 Therapeutics expands board with two new directors - Investing.com
Tue, 04 Mar 2025
CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 - Yahoo Finance
Fri, 18 Oct 2024
CAMP4 Rings the Opening Bell - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 2.63e+006 (%) |
| Held by Institutions | 35.4 (%) |
| Shares Short | 360 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.139e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 152.4 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 652000 % |
| Gross Profit (p.s.) | -1.89 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | -11.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 323880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|